NEURAXIAL ANESTHESIA AND ANTICOAGULATION
Dr. Terese Horlocker
Professor, Anesthesiology and Orthopedics
Mayo Clinic
Rochester, MN USA
Dabigatran
Dabigatran etexilate is a prodrug that specifically and reversibly inhibits both free and clot-bound thrombin. The drug is absorbed from the gastrointestinal tract with a bioavailability of 5%(20). Once absorbed it is converted by esterases into its active metabolite, dabigatran. Plasma levels peak at two hours. The half-life is eight hours after a single dose and up to 17 hours after multiple doses. It is likely that once daily dosing will be possible for some indications because of the prolonged half-life. Because 80% of the drug is excreted unchanged by the kidneys, it is contraindicated in patients with renal failure(21). Dabigatran prolongs the aPTT, but its effect is not linear and reaches
a plateau at higher doses. However, the ecarin clotting time (ECT) and thrombin time (TT) are particularly sensitive and display a linear dose response at therapeutic concentrations. Reversal of anticoagulant effect is theoretically possible through administration of recombinant factor VIIa, although this has not been attempted clinically(21). Indeed, product labeling suggests that dialysis may be considered for patients with significant bleeding due to dabigatran.
Given the irreversibility of dabigtran, the prolonged half-life and the uncertainty of an individual patient’s renal function, dabigatran should be discontinued ideally seven days (and a minimum of five days) prior to neuraxial block. Consider documentation of reversal of anticoagulant effect (assessment of a TT or ECT) if less than seven days has elapsed since discontinuation. Neuraxial catheters should be removed at least six hours prior to initiation of dabigatran therapy(22).
Anesthetic Management of the Anticoagulated Patient
The decision to perform spinal or epidural anesthesia/analgesia and the timing of catheter removal in a patient receiving thromboprophylaxis should be made on an individual basis, weighing the small, though definite risk of spinal hematoma with the benefits of regional anesthesia for a specific patient. Alternative anesthetic and analgesic techniques exist for patients considered to be at an unacceptable risk. The patient’s coagulation status should be optimized at the time of spinal or epidural needle/catheter placement, and the level of anticoagulation must be carefully monitored during the period of epidural catheterization (Table 1). It is important to note that patients respond with variable sensitivities to anticoagulant medications. Indwelling catheters should not be removed in the presence of a significant coagulopathy, as this appears to significantly increase the risk of spinal hematoma (2,3). In addition, communication between clinicians involved in the perioperative
management of patients receiving anticoagulants for thromboprophylaxis is essential in order to
decrease the risk of serious hemorrhagic complications. The patient should be closely monitored in
the perioperative period for signs of cord ischemia. If spinal hematoma is suspected, the treatment of choice is immediate decompressive laminectomy. Recovery is unlikely if surgery is postponed for more than 10-12 hours; less than 40% of the patients in the series by Vandermeulen et al. (2) had partial or good recovery of neurologic function.
Recommendations for Management of Patients Receiving Neuraxial Blockade and
Anticoagulant Drugs
Warfarin
Discontinue chronic warfarin therapy 4–5 days before spinal procedure and evaluate INR. INR should be within the normal range at time of procedure to ensure adequate levels of all vitamin K-dependent factors. Postoperatively, daily INR assessment with catheter removal occurring with INR< 1.5
______________________________________________________________________________
Antiplatelet Medications
No contraindications with aspirin or other NSAIDs. Clopidogrel and ticagrelorl should be discontinued 5-77 days, prasugrel 7-10 days, and ticlopidine 14 days, prior to procedure. GP IIb/IIIa inhibitors should be discontinued to allow recovery of platelet function prior to procedure (8 hours for tirofiban and eptifibatide, 24–48 hours for abciximab).
______________________________________________________________________________
Thrombolytics/fibrinolytics
There are no available data to suggest a safe interval between procedure and initiation or discontinuation of these medications. Follow fibrinogen level and observe for signs of neural compression.
LMWH
Delay procedure at least 12 hours from the last dose of thromboprophylaxis LMWH dose. For "treatment" dosing of LMWH, at least 24 hours should elapse prior to procedure. LMWH should not be administered within 24 hours after the procedure. Indwelling epidural catheters should be maintained only with once daily dosing of LMWH and strict avoidance of additional hemostasis altering medications, including ketorolac.
_______________________________________________________________________________________
Unfractionated SQ heparin
There are no contraindications to neuraxial procedure if total daily dose is less than 10,000 units. For higher dosing regimens, increase neurologic monitoring and cautiously co-administer antiplatelet medications.
________________________________________________________________________________
Unfractionated IV heparin
Delay needle/catheter placement 2–4 hours after last dose, document normal aPTT. Heparin may be restarted 1 hour following procedure. Sustained heparinization with an indwelling neuraxial catheter associated with increased risk; monitor neurologic status aggressively.
________________________________________________________________________________
Dabigatran
Discontinue 5-7 days prior to procedure; for shorter time periods, document normal TT. First postoperative dose 24 h after needle placement and 2 h post catheter removal (which ever is later).
________________________________________________________________________________
Rivaroxaban
Needle placement 3-5 d after discontinuation. No neuraxial or deep/plexus catheters during rivaroxaban therapy. First dose 6 h postoperatively.
References
1. Tryba M. [Epidural regional anesthesia and low molecular heparin: Pro]. Anasthesiol
Intensivmed Notfallmed Schmerzther 1993;28:179-81.
2. Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia.
Anesth Analg 1994;79:1165-77.
3. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial
blockades in Sweden 1990-1999. Anesthesiology 2004;101:950-9.
4. Horlocker TT, Wedel DJ, Rowlingson JC, Enneking FK, Kopp SL, Benzon HT, Brown DL,
Heit JA, Mulroy MF, Rosenquist RW, Tryba M, Yuan CS. Regional anesthesia in the
patient receiving antithrombotic or thrombolytic therapy: American Society of Regional
Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain
Med 2010;35:64-101.
5. Benzon HT, Avram MJ, Benzon HA, Kirby-Nolan M, Nader A. Factor VII levels and
international normalized ratios in the early phase of warfarin therapy. Anesthesiology
2010;112:298-304.
6. Odoom JA, Sih IL. Epidural analgesia and anticoagulant therapy. Experience with one
thousand cases of continuous epidurals. Anaesthesia 1983;38:254-9.
7. Horlocker TT, Wedel DJ, Schlichting JL. Postoperative epidural analgesia and oral
anticoagulant therapy. Anesth Analg 1994;79:89-93.
8. Wu CL, Perkins FM. Oral anticoagulant prophylaxis and epidural catheter removal. Reg
Anesth 1996;21:517-24.
9. Parvizi J, Viscusi ER, Frank HG, Sharkey PF, Hozack WJ, Rothman RR. Can epidural
anesthesia and warfarin be coadministered? Clin Orthop Relat Res 2007;456:133-7.
10. Rao TL, El-Etr AA. Anticoagulation following placement of epidural and subarachnoid
catheters: an evaluation of neurologic sequelae. Anesthesiology 1981;55:618-20.
11. Ruff RL, Dougherty JH, Jr. Complications of lumbar puncture followed by anticoagulation.
Stroke 1981;12:879-81.
12. Liu SS, Mulroy MF. Neuraxial anesthesia and analgesia in the presence of standard heparin.
Reg Anesth Pain Med 1998;23:157-63.
13. Sandhu H, Morley-Forster P, Spadafora S. Epidural hematoma following epidural analgesia
in a patient receiving unfractionated heparin for thromboprophylaxis. Reg Anesth Pain Med
2000;25:72-5.
14. Greaves JD. Serious spinal cord injury due to haematomyelia caused by spinal anaesthesia
in a patient treated with low-dose heparin. Anaesthesia 1997;52:150-4.
15. Bergqvist D, Lindblad B, Matzsch T. Low molecular weight heparin for
thromboprophylaxis and epidural/spinal anaesthesia--is there a risk? Acta Anaesthesiol
Scand 1992;36:605-9.
16. Horlocker TT, Wedel DJ. Neuraxial block and low-molecular-weight heparin: balancing
perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998;23:164-77.
17. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, Mulroy MF,
Rosenquist RW, Rowlingson J, Tryba M, Yuan CS. Regional anesthesia in the
131
anticoagulated patient: defining the risks (the second ASRA Consensus Conference on
Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003;28:172-97.
18. Schroeder DR. Statistics: detecting a rare adverse drug reaction using spontaneous reports.
Reg Anesth Pain Med 1998;23:183-9.
19. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW.
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
20. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
2008;133:234S-56S.
21. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics
of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet
2009;48:1-22.
22. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional
anaesthesia and antithrombotic agents: recommendations of the European Society of
Anaesthesiology. Eur J Anaesthesiol 2010;27:999-1015.
23. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig
C, Misselwitz F, Kalebo P. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY
59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006;114:2374-
81.
24. Fisher WD, Eriksson BI, Bauer KA, Borris L, Dahl OE, Gent M, Haas S, Homering M,
Huisman MV, Kakkar AK, Kalebo P, Kwong LM, Misselwitz F, Turpie AG. Rivaroxaban
for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb
Haemost 2007;97:931-7.
25. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F,
Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee
arthroplasty. N Engl J Med 2008;358:2776-86.
26. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of preeclampsia
among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in
Pregnancy) Collaborative Group. Lancet 1994;343:619-29.
27. Horlocker TT, Bajwa ZH, Ashraf Z, Khan S, Wilson JL, Sami N, Peeters-Asdourian C,
Powers CA, Schroeder DR, Decker PA, Warfield CA. Risk assessment of hemorrhagic
complications associated with nonsteroidal antiinflammatory medications in ambulatory
pain clinic patients undergoing epidural steroid injection. Anesth Analg 2002;95:1691-7.
28. Horlocker TT, Wedel DJ, Schroeder DR, Rose SH, Elliott BA, McGregor DG, Wong GY.
Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated
with regional anesthesia. Anesth Analg 1995;80:303-9.